
Collaborations Pharmaceuticals, Inc. Awarded An SBIR from NIH/NIDA to Develop Drugs for Opioid Abuse Treatment
The National Institute on Drug Abuse has awarded a $256,220 SBIR grant to Collaborations Pharmaceuticals, Inc. RALEIGH, NC, USA, April 13, 2022 /EINPresswire.com/ -- “Collaborations Pharmaceuticals, Inc. (CPI) are excited to be awarded a Phase I SBIR from the National Institutes of Health / National Institute on Drug Abuse for their project “New therapeutic approaches to identifying molecules for opioid abuse treatment”. This is specifically part of the HEAL Initiative: America’s Startups and Small …